Form 4: Enanta Pharmaceuticals Director Bruce Carter Acquires Stock Options
SEC Form 4 Filing
Director Bruce L A Carter of Enanta Pharmaceuticals acquired stock options on March 6, 2024.
Summary
- On March 6, 2024, Bruce L A Carter, a director of Enanta Pharmaceuticals, acquired 15,700 stock options with an exercise price of $15.66.
- These options become exercisable monthly over one year, starting March 6, 2024, with the final installment vesting before the 2025 annual meeting of stockholders.
- Following the transaction, Carter directly owns 15,700 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard insider transaction filing. The acquisition of options could be seen as a slightly positive signal, but it's not a major event.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is crucial for maintaining market confidence.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of the transaction: Bruce Carter acquired stock options. |
| 03/06/2024 | Start date for monthly vesting of the stock options. |
| 03/06/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.